12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
10 citations
,
November 2024 in “Nature Reviews Cardiology” Skin conditions can signal heart issues, highlighting the need for integrated care.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
9 citations
,
May 2023 in “Inflammation Research” New small molecule drugs show promise in treating complex skin diseases but need more safety research.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
4 citations
,
July 2025 in “Frontiers in Immunology” Early intervention with JAK inhibitors may prevent alopecia areata progression.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
4 citations
,
March 2024 in “Quality of Life Research” More severe hair loss in alopecia areata greatly impacts patients and caregivers.
4 citations
,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
3 citations
,
January 2024 in “Annals of Dermatology” The criteria help doctors diagnose and treat alopecia areata more effectively.
2 citations
,
April 2025 in “Dermatology and Therapy” Alopecia areata affects quality of life more in adolescents than adults.
2 citations
,
October 2024 in “Dermatology and Therapy” Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
2 citations
,
March 2024 in “PubMed” More research is needed on alopecia areata treatments and its psychological effects.
2 citations
,
October 2023 in “Dermatology and therapy” Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
1 citations
,
January 2026 Use personalized cosmeceuticals for safe, effective hair and scalp treatment.
1 citations
,
December 2025 in “Scientific Reports” A machine learning model can predict alopecia areata early using specific gene markers.
1 citations
,
November 2025 in “Frontiers in Immunology” More research is needed to understand and manage rheumatoid arthritis better.
1 citations
,
April 2025 in “Dermatology and Therapy” Vitiligo's impact varies widely, affecting both emotions and social life, not just physical symptoms.
1 citations
,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
1 citations
,
September 2023 in “Journal of drugs in dermatology” Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.
1 citations
,
October 2021 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for severe alopecia areata show promise but lack standard approval.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
April 2026 in “International Journal of Drug Delivery Technology” Alopecia can often be managed effectively with various treatments, but early diagnosis is crucial for preventing permanent hair loss.
STS01 1% effectively promotes hair regrowth with minimal side effects.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
March 2026 in “Dermatology and Therapy” More severe alopecia areata can lower quality of life.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.